Press Releases Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Delayed Nasdaq Other stock markets 12:20:51 2024-05-23 pm EDT			5-day change	1st Jan Change
2.04 ^USD	+2.51%		+0.49%	+13.65%

May. 08	Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board	CI
May. 07	Eterna Therapeutics Inc. to Present at the ASGCT 27Th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board	May. 08	AQ
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus	May. 07	AQ
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases	May. 07	AQ
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors	Feb. 20	AQ
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)	Jan. 03	AQ
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer	Dec. 20	AQ
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing	Dec. 14	AQ
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors	Nov. 01	AQ
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics	23-09-06	AQ
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors	23-09-05	AQ
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing	23-07-18	AQ
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors	23-07-12	AQ
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics	23-05-02	AQ
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights	23-03-21	AQ
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications	23-02-23	AQ
Eterna Therapeutics : Material Agreement - Form 8-K	22-12-05	PU
Eterna Therapeutics : Material Agreement - Form 8-K	22-11-25	PU
Eterna Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	22-11-23	PU
BROOKLYN IMMUNOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	22-10-14	AQ
BROOKLYN IMMUNOTHERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	22-10-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Press Releases

Filters